March 17, 2017 / 11:53 AM / 4 months ago

BRIEF-Galena presents positive early-stage data on GALE-301

1 Min Read

March 17 (Reuters) - Galena Biopharma Inc

* Galena biopharma presents positive final gale-301 (e39) phase 1/2a clinical trial data

* Galena biopharma - patients with primary disease who received 1000mcg dose appear to maintain a statistically significant benefit while those with recurrent disease were not

* Galena biopharma inc - final data from early stage clinical trial demonstrates that gale-301 is well tolerated Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below